CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 22 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q1 2016. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $833,000 | -34.6% | 5,045,870 | 0.0% | 0.49% | -33.0% |
Q2 2022 | $1,273,000 | -52.6% | 5,045,870 | 0.0% | 0.73% | -56.9% |
Q1 2022 | $2,684,000 | -13.6% | 5,045,870 | 0.0% | 1.68% | -1.3% |
Q4 2021 | $3,107,000 | -39.6% | 5,045,870 | 0.0% | 1.71% | -33.5% |
Q3 2021 | $5,147,000 | -44.3% | 5,045,870 | 0.0% | 2.57% | -46.8% |
Q2 2021 | $9,234,000 | -7.1% | 5,045,870 | 0.0% | 4.82% | -25.5% |
Q1 2021 | $9,940,000 | +57.6% | 5,045,870 | 0.0% | 6.48% | +50.6% |
Q4 2020 | $6,307,000 | -30.6% | 5,045,870 | 0.0% | 4.30% | -42.2% |
Q3 2020 | $9,083,000 | -78.5% | 5,045,870 | 0.0% | 7.44% | -69.5% |
Q2 2020 | $42,335,000 | +60.1% | 5,045,870 | 0.0% | 24.44% | -1.6% |
Q1 2020 | $26,440,000 | -4.0% | 5,045,870 | 0.0% | 24.84% | +22.1% |
Q4 2019 | $27,550,000 | +13.5% | 5,045,870 | +1.2% | 20.34% | -8.5% |
Q3 2019 | $24,281,000 | -29.7% | 4,985,870 | 0.0% | 22.22% | -21.4% |
Q2 2019 | $34,552,000 | -0.3% | 4,985,870 | 0.0% | 28.29% | +7.4% |
Q1 2019 | $34,652,000 | +46.0% | 4,985,870 | +22.7% | 26.33% | -2.4% |
Q4 2018 | $23,727,000 | -22.1% | 4,062,791 | 0.0% | 26.99% | +4.8% |
Q3 2018 | $30,471,000 | +54.2% | 4,062,791 | +3.8% | 25.76% | +53.4% |
Q2 2018 | $19,765,000 | -16.0% | 3,913,874 | +1.5% | 16.80% | -30.5% |
Q1 2018 | $23,528,000 | -14.1% | 3,856,985 | 0.0% | 24.16% | +0.1% |
Q4 2017 | $27,385,000 | +2.4% | 3,856,985 | +3.2% | 24.14% | +5.6% |
Q3 2017 | $26,733,000 | +13.5% | 3,738,925 | 0.0% | 22.86% | -26.8% |
Q2 2017 | $23,555,000 | -23.6% | 3,738,925 | 0.0% | 31.22% | -32.9% |
Q1 2017 | $30,846,000 | +42.4% | 3,738,925 | +45.8% | 46.50% | +22.3% |
Q4 2016 | $21,665,000 | +29.6% | 2,563,925 | 0.0% | 38.01% | +29.7% |
Q3 2016 | $16,717,000 | +118.1% | 2,563,925 | 0.0% | 29.31% | +1079.6% |
Q2 2016 | $7,666,000 | +65.2% | 2,563,925 | 0.0% | 2.48% | +31.9% |
Q1 2016 | $4,641,000 | +9.7% | 2,563,925 | 0.0% | 1.88% | +20.2% |
Q4 2015 | $4,230,000 | -2.2% | 2,563,925 | -6.8% | 1.57% | -14.6% |
Q3 2015 | $4,325,000 | -19.8% | 2,750,000 | +57.1% | 1.84% | +5.6% |
Q2 2015 | $5,390,000 | – | 1,750,000 | – | 1.74% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Knoll Capital Management, LLC | 5,045,870 | $42,335,000 | 24.44% |
MANGROVE PARTNERS IM, LLC | 552,200 | $4,633,000 | 1.13% |
ETF MANAGERS GROUP, LLC | 3,707,912 | $31,109,000 | 1.10% |
Ikarian Capital, LLC | 1,350,000 | $11,327,000 | 0.90% |
GENERAL AMERICAN INVESTORS CO INC | 712,400 | $5,977,000 | 0.76% |
AdvisorShares Investments LLC | 189,814 | $1,593,000 | 0.68% |
Ikarian Capital, LLC | 1,000,000 | $8,390,000 | 0.67% |
Granite Point Capital Management, L.P. | 1,123,600 | $9,427,000 | 0.48% |
Carmignac Gestion | 3,773,440 | $31,659,000 | 0.44% |
Omnia Family Wealth, LLC | 32,356 | $271,467,000 | 0.27% |